The invention relates to a chimeric antigen receptor of a cell for expressing a CD30 surface antigen in a targeted mode. The chimeric antigen receptor of the cell is characterized by comprising a CD30 binding structural domain, a membrane spanning domain and an intracellular signal structural domain; and the amino acid sequence of the CD30 binding structural domain is shown as SEQ ID NO:1. The invention further relates to nucleic acid for coding the chimeric antigen receptor, and further relates to a recombinant expression vector for expressing the chimeric antigen receptor. The chimeric antigen receptor is expressed in T cells and the obtained CAR T cells can effectively and specifically express malignant cells of the CD30 surface antigen in a targeted mode, so that an efficient method with fewer side effects and adverse reactions is provided for treating some tumours of expressing the CD30 surface antigen such as hodgkin lymphoma.